Halozyme Therapeutics | HALO - أصول متداولة





أصول متداولة تغيير تاريخ
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Amarin USD 626.02M 23.87M 2026-03
Amgen USD 31.48B 2.42B 2026-03
Baxter International USD 6.85B 25M 2026-03
Cara Therapeutics USD 31.54M 6.9M 2025-12
Cytokinetics USD 839.46M 77.51M 2026-03
DBV Technologies USD 212.94M 124.06M 2025-12
Eli Lilly USD 54.84B 794M 2026-03
Esperion Therapeutics USD 459.46M 3.11M 2026-03
Halozyme Therapeutics USD 1B 177.83M 2026-03
Intrexon USD 23.72M 45.04M 2024-06
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
MannKind USD 251.16M 40.42M 2026-03
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Pfizer USD 42.82B 76M 2026-03
Rigel Pharmaceuticals USD 214.93M 39.53M 2025-09
United Therapeutics USD 2.87B 830.5M 2026-03
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12